Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PEG-ELECTROLYTES

All products: not a benefit

Colyte · DIN 00677442 · · Pd-4L Pk

Listed, not a benefitMarketed · checked 2026-09-02
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Colyte · DIN 00677442 Manufacturer: Pendopharm, Division of Pharmascience Inc.; listing date 1996-10-01 Health Canada: Marketed since 2013-04-01 · brand COLYTE · ATC A06AD65 MACROGOL, COMBINATIONS · form Powder for solution · route Oral, Nasogastric · ingredients SODIUM CHLORIDE 20.87 MG/G, SODIUM SULFATE 81.2 MG/G, SODIUM BICARBONATE 24.02 MG/G, POLYETHYLENE GLYCOL 3350 857.69 MG/G, POTASSIUM CHLORIDE 10.65 MG/G · company Pendopharm division of pharmascience inc · schedule Ethical
Check this DIN again · Health Canada product record

Colyte: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6616 · Verify on the e-Formulary ↗ (DIN 00677442)

Source record
DIN 00677442: Colyte Raw flags: notABenefit=Y, sec3=Y Item: 401200040; group id 549; item number 1481; lccId None; manufacturer id PEN Source form: Pd-4L Pk; strength: None Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00677442 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6616
Interchangeable products
JampLyte · DIN 02378329 · $16.4640 PegLyte Powder · DIN 00777838 · $16.4640
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00677442
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (40:12 Replacement Agents) and how they are covered

Matched class: 40:12 Replacement Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ELECTROLYTE & DEXTROSE 40:12 Replacement Agents

ELECTROLYTE & DEXTROSE

· 2 products · General benefit · strengths: · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 40:12
Full class listing Related classes: 40:18 Potassium-Removing Resins, 40:28 Diuretics, 40:40 Uricosuric Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: constipation
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: BISACODYL BISACODYL · General benefit INDICATIONS AND CLINICAL USE DULCOLAX is indicated for: • Relief of occasional constipation • Under medical supervision, for the preparation of diagnostic procedures, in pre- and postoperative treatment, and in conditions which require defecation to be facilitated. PM: https://pdf.hres.ca/dpd_pm/00076868.PDF; date November 3, 2022; DIN 00003875; fetched 2026-09-10 Product monograph PRUCALOPRIDE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS RESOTRAN® (prucalopride succinate tablets) is indicated for: • The treatment of chronic idiopathic constipation in adult female patients in whom laxatives failed to provide adequate relief. PM: https://pdf.hres.ca/dpd_pm/00073288.PDF; date NOV 08, 2023; DIN 02377012; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Adults Colyte® (PEG 3350 and Electrolytes) is indicated for:  bowel cleansing prior to colonoscopy or barium enema x-ray examination or surgical procedures requiring a clean colon.  the treatment of constipation https://pdf.hres.ca/dpd_pm/00061814.PDF PM date: March 25, 2021 Source product: COLYTE; DIN 00677442; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Colyte: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026